AU2008292186B9 - Liquid formulation of G-CSF conjugate - Google Patents

Liquid formulation of G-CSF conjugate Download PDF

Info

Publication number
AU2008292186B9
AU2008292186B9 AU2008292186A AU2008292186A AU2008292186B9 AU 2008292186 B9 AU2008292186 B9 AU 2008292186B9 AU 2008292186 A AU2008292186 A AU 2008292186A AU 2008292186 A AU2008292186 A AU 2008292186A AU 2008292186 B9 AU2008292186 B9 AU 2008292186B9
Authority
AU
Australia
Prior art keywords
csf
aqueous preparation
preparation according
polymer
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2008292186A
Other languages
English (en)
Other versions
AU2008292186A1 (en
AU2008292186B2 (en
Inventor
Walter Hinderer
Christian Scheckermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of AU2008292186A1 publication Critical patent/AU2008292186A1/en
Application granted granted Critical
Publication of AU2008292186B2 publication Critical patent/AU2008292186B2/en
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOGENERIX AG
Publication of AU2008292186B9 publication Critical patent/AU2008292186B9/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008292186A 2007-08-27 2008-08-27 Liquid formulation of G-CSF conjugate Active 2030-11-12 AU2008292186B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07115047.8 2007-08-27
EP07115047 2007-08-27
PCT/EP2008/061232 WO2009027437A1 (en) 2007-08-27 2008-08-27 Liquid formulation of g-csf conjugate

Publications (3)

Publication Number Publication Date
AU2008292186A1 AU2008292186A1 (en) 2009-03-05
AU2008292186B2 AU2008292186B2 (en) 2014-02-27
AU2008292186B9 true AU2008292186B9 (en) 2014-07-03

Family

ID=39862881

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008292186A Active 2030-11-12 AU2008292186B9 (en) 2007-08-27 2008-08-27 Liquid formulation of G-CSF conjugate

Country Status (24)

Country Link
US (1) US8546328B2 (https=)
EP (2) EP2578235A3 (https=)
JP (2) JP5570988B2 (https=)
KR (1) KR20100052501A (https=)
CN (2) CN101827864A (https=)
AU (1) AU2008292186B9 (https=)
BR (1) BRPI0815975B8 (https=)
CA (1) CA2696594C (https=)
CY (1) CY1115908T1 (https=)
DE (1) DE202008017456U1 (https=)
DK (1) DK2197919T3 (https=)
EA (1) EA020069B1 (https=)
ES (1) ES2476915T3 (https=)
HR (1) HRP20140590T1 (https=)
IL (1) IL204190A (https=)
MX (1) MX2010002448A (https=)
NZ (1) NZ583276A (https=)
PL (1) PL2197919T3 (https=)
PT (1) PT2197919E (https=)
RS (1) RS53404B (https=)
SI (1) SI2197919T1 (https=)
UA (1) UA98001C2 (https=)
WO (1) WO2009027437A1 (https=)
ZA (1) ZA201000798B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107412737A (zh) * 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
MX2012010661A (es) 2010-03-17 2013-03-25 Biogenerix Gmbh Metodo para obtener factor estimulante de colonias de granulocitos (g-csf) humano recombinante biologicamente activo.
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
WO2017181920A1 (zh) * 2016-04-18 2017-10-26 江苏恒瑞医药股份有限公司 一种重组人粒细胞集落刺激因子的制备方法
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
WO2019212429A2 (en) * 2018-05-04 2019-11-07 İlkogen İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable hybrid fc fusion g-csf formulation
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
CN119698274A (zh) * 2022-08-19 2025-03-25 亿一生物医药开发(上海)有限公司 包含g-csf的制剂及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US20040037803A1 (en) * 2000-09-01 2004-02-26 Yasushi Sato Solution preparations stabilized over long time
WO2005039620A1 (de) * 2003-10-20 2005-05-06 Hexal Biotech Forschungs Gmbh Stabile wässrige g-csf-haltige zusammensetzungen
US20050250678A1 (en) * 2004-01-08 2005-11-10 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2006074467A2 (en) * 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20070009478A1 (en) * 2005-06-01 2007-01-11 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (https=) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US5675941A (en) 1983-12-09 1997-10-14 Dykmans; Maximiliaan J. Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Ｇ−ｃｓｆの精製方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
AU677789B2 (en) 1992-07-02 1997-05-08 Collagen Corporation Biocompatible polymer conjugates
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DK0726778T3 (da) 1994-02-08 2001-09-24 Amgen Inc Oral administration af kemisk modificerede proteiner
ES2312166T3 (es) 1994-02-23 2009-02-16 Kyowa Hakko Kogyo Co., Ltd Acelerador del crecimiento plaquetario.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000506119A (ja) 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
CA2278178C (en) 1997-01-16 2012-09-25 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
WO1998055500A1 (en) 1997-06-06 1998-12-10 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
AU2001263149A1 (en) 2000-05-12 2001-11-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
PL219131B1 (pl) 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
KR101154343B1 (ko) 2003-08-08 2012-07-05 프레제니우스 카비 도이치란트 게엠베하 히드록시알킬 스타치 및 ｇ-ｃｓｆ의 컨쥬게이트
US7585496B2 (en) 2003-11-04 2009-09-08 Lek Pharmaceuticals D.D. Stable pharmaceutical composition granulocyte-colony stimulating factor
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
ES2390885T3 (es) 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
DE102004036909B4 (de) 2004-07-29 2007-04-05 Infineon Technologies Ag Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung
WO2006097944A2 (en) 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US20040037803A1 (en) * 2000-09-01 2004-02-26 Yasushi Sato Solution preparations stabilized over long time
WO2005039620A1 (de) * 2003-10-20 2005-05-06 Hexal Biotech Forschungs Gmbh Stabile wässrige g-csf-haltige zusammensetzungen
US20050250678A1 (en) * 2004-01-08 2005-11-10 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2006074467A2 (en) * 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20070009478A1 (en) * 2005-06-01 2007-01-11 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIEDMONTE D. M., et al, "Formulation of Neulasta® (pegfilgrastim)", Advanced Drug Delivery Reviews, 2008, vol 60, no 1, pages 50-58 *
SCHNEIDER A., et al, "A role for G-CSF (Granulocyte colony stimulating factor) in the Central Nervous System", Cell Cycle, vol 4, no 12, pages 1753-1757 *

Also Published As

Publication number Publication date
EP2197919B1 (en) 2014-04-09
DK2197919T3 (da) 2014-07-07
JP2014101362A (ja) 2014-06-05
BRPI0815975B8 (pt) 2021-05-25
EA020069B1 (ru) 2014-08-29
RS53404B (sr) 2014-10-31
ES2476915T3 (es) 2014-07-15
BRPI0815975B1 (pt) 2019-04-02
CN104689333B (zh) 2018-05-29
KR20100052501A (ko) 2010-05-19
PT2197919E (pt) 2014-07-17
PL2197919T3 (pl) 2014-09-30
HRP20140590T1 (hr) 2014-08-15
US20110053844A1 (en) 2011-03-03
NZ583276A (en) 2012-06-29
CN104689333A (zh) 2015-06-10
EP2578235A2 (en) 2013-04-10
DE202008017456U1 (de) 2009-08-27
EP2197919A1 (en) 2010-06-23
JP5570988B2 (ja) 2014-08-13
CA2696594A1 (en) 2009-03-05
ZA201000798B (en) 2010-10-27
JP5836351B2 (ja) 2015-12-24
MX2010002448A (es) 2010-10-04
IL204190A (en) 2015-01-29
EA201070315A1 (ru) 2010-08-30
SI2197919T1 (sl) 2014-09-30
JP2010536929A (ja) 2010-12-02
BRPI0815975A2 (pt) 2015-02-18
CN101827864A (zh) 2010-09-08
CY1115908T1 (el) 2017-01-25
UA98001C2 (uk) 2012-04-10
CA2696594C (en) 2019-03-19
US8546328B2 (en) 2013-10-01
AU2008292186A1 (en) 2009-03-05
AU2008292186B2 (en) 2014-02-27
WO2009027437A1 (en) 2009-03-05
EP2578235A3 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
US8207112B2 (en) Liquid formulation of G-CSF conjugate
AU2008292186B9 (en) Liquid formulation of G-CSF conjugate
US9492557B2 (en) Derivatisation of granulocyte colony-stimulating factor
CA2452582C (en) G-csf conjugates
JP5336372B2 (ja) Ｇ−ｃｓｆ部位特異的モノコンジュゲート
US20090247450A1 (en) G-csf liquid formulation
EP1768700B1 (en) Conjugates comprising gm-csf and a polymer
HK1148292A (en) Liquid formulation of g-csf conjugate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
SREP Specification republished
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: LONQUEX LIPEGFILGRASTIM (RBE)

Filing date: 20151112

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: LONQUEX LIPEGFILGRASTIM (RBE)

Filing date: 20151112

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: LONQUEX LIPEGFILGRASTIM (RBE)

Filing date: 20151112

Extension date: 20301112